Search Results - "Devos, T"

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis by Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, Vannucchi, A M

“…Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET…”
Get full text

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients by Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, Vannucchi, A M

Get full text

KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia by Willemze, R, Rodrigues, C A, Labopin, M, Sanz, G, Michel, G, Socié, G, Rio, B, Sirvent, A, Renaud, M, Madero, L, Mohty, M, Ferra, C, Garnier, F, Loiseau, P, Garcia, J, Lecchi, L, Kögler, G, Beguin, Y, Navarrete, C, Devos, T, Ionescu, I, Boudjedir, K, Herr, A-L, Gluckman, E, Rocha, V

“…Donor killer cell immunoglobulin-like receptor (KIR)-ligand incompatibility is associated with decreased relapse incidence (RI) and improved leukemia-free…”
Get full text

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence by Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P

“…RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. The objective of this study was to determine…”
Get full text

Diagnosing nocturnal paroxysmal hemoglobinuria: a single‐center 4‐year experience by Mercier, T., Devos, T., Mukovnikova, M., Boeckx, N.

“…Summary Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease and can present as a wide range of signs and symptoms. As such, the indication…”
Get full text

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence by Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P

Get full text

Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice by Luyckx, A, Schouppe, E, Rutgeerts, O, Lenaerts, C, Koks, C, Fevery, S, Devos, T, Dierickx, D, Waer, M, Van Ginderachter, J A, Billiau, A D

“…To date, myeloid-derived suppressor cells (MDSC) have been best studied in cancer, where they represent an escape mechanism for immune surveillance. MDSC are…”
Get full text

Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years by Devos, T., Thiessen, S., Cuyle, P. J., Meersseman, W., Delforge, M.

Get full text

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS by Kiladjian, J.‐J., Tefferi, A., Passamonti, F., Vannucchi, A., Talpaz, M., Cervantes, F., Harrison, C. N., Mesa, R. A., Mascarenhas, J., Schaap, N., Verstovsek, S., Devos, T., Rose, S., Zhang, J., Sy, O., Pardanani, A.

Get full text

P699: REAL‐LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME‐POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5‐YEAR‐DATA FROM A BELGIAN REGISTRY by Devos, T., Havelange, V., Theunissen, K., Meers, S., Benghiat, F. S., Gadisseur, A., Vanstraelen, G., Vellemans, H., Bailly, B., Granacher, N., Lewalle, P., De Becker, A., Van Eygen, K., Lejeune, M., Janssen, M., Triffet, A., Vrelust, I., Deeren, D., Mazure, D., Beck, M., Sebti, H., Selleslag, D.

Get full text

S198: BET INHIBITOR PELABRESIB (CPI‐0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR‐NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY by Mascarenhas, J., Kremyanskaya, M., Patriarca, A., Harrison, C., Bose, P., Rampal, R. K., Palandri, F, Devos, T., Passamonti, F., Hobbs, G., Talpaz, M., Vannucchi, A., Kiladjian, J.‐J., Verstovsek, S., Hoffman, R., Salama, M. E., Chen, D., Taverna, P., Chang, A., Colak, G., Klein, S., Gupta, V.

Get full text

P1361: TREATMENT OF SEVERE STEROID‐REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE‐BLIND MULTI‐CENTER HOVON‐113 TRIAL by Oosten, L., Pel, M., Holt, B., Bach, E., Cross, M., Roelofs, H., Meij, P., Wieles, B., Zwaginga, J. J., Lankester, A., Veelken, H., Platzbecker, U., Sanchez‐Guijo, F., Algeri, M., Locatelli, F., Devos, T., Cornelissen, J., Niederwieser, D., Fibbe, W.

Get full text

P995: MYELOID NEOPLASMS‐ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST‐POLYCYTHEMIA VERA AND POST‐ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT by Mora, B., Guglielmelli, P., Kuykendall, A., Maffioli, M., Rotunno, G., Komrokji, R. S., Palandri, F., Kiladjian, J.‐J., Iurlo, A., Auteri, G., Cattaneo, D., De Stefano, V., Salmoiraghi, S., Devos, T., Cervantes, F., Merli, M., Campagna, A., Benevolo, G., Brociner, M., Albano, F., Gotlib, J., Caramella, M., Ruggeri, M., Ross, D. M., Orsini, F., Pessina, C., Colugnat, I., Pallotti, F., Barbui, T., Bertù, L., Della Porta, M. G., Vannucchi, A. M., Passamonti, F.

Get full text

P1030: MANIFEST‐2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE‐BLIND, ACTIVE‐CONTROL STUDY OF PELABRESIB (CPI‐0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR‐NAÏVE MYELOFIBROSIS PATIENTS by Harrison, C., Rampal, R. K., Gupta, V., Verstovsek, S., Talpaz, M., Kiladjian, J.‐J., Mesa, R., Kuykendall, A., Vannucchi, A., Palandri, F., Grosicki, S., Devos, T., Jourdan, E., Wondergem, M. J., Al‐Ali, H. K., Buxhofer‐Ausch, V., Alvarez‐Larrán, A., Akhani, S., Muñoz‐Carerras, R., Sheykin, Y., Colak, G., Harris, M., Mascarenhas, J.

Get full text

Post-cryopreservation viability of mesenchymal stem cells by Van Campenhout, A, Swinnen, L, Klykens, J, Devos, T, Verhoef, G

Get full text

Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study by Zelis, N., Devos, T., Dierickx, D., Janssens, A., Raddoux, J., Verhoef, G., Delforge, M.

“…Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with…”
Get full text

A 75-year-old missionary with fever, splenomegaly and pancytopenia by Masfrancx, D, De Munter, P, Devos, T

“…We present a case of hyperreactive malarial splenomegaly, a disease which is exceptional in Caucasian people, but which is expected to become more important…”
Get full text

A novel approach for BCR-ABL1 standardization to improve International Scale estimation by Maes, B., Bakkus, M., Boeckx, N., Boone, E., Cauwelier, B., Denys, B., De Schouwer, P., Devos, T., El Housni, H., Hillen, F., Jacobs, K., Lambert, F., Louagie, H., Maes, M.-B., Meeus, P., Moreau, E., Nollet, F., Peeters, K., Saussoy, P., Van Lint, P., Vaerman, J.-L., Vaeyens, F., Vandepoele, K., Vannuffel, P., Ver Elst, K., Vermeulen, K., Bruyndonckx, R.

“…Summary Introduction Standardization of BCR‐ABL1 messenger RNA quantification by real‐time PCR on the International Scale (IS) is critical for monitoring…”
Get full text

Myelofibrosis patients in Belgium: disease characteristics by Devos, T., Zachée, P., Bron, D., Noens, L., Droogenbroeck, J. Van, Mineur, P., Beguin, Y., Berneman, Z., Benghiat, F. S., Kentos, A., Chatelain, C., Demuynck, H., Lemmens, J., Eygen, K. Van, Theunissen, K., Trullemans, F., Pierre, P., Pluymers, W., Knoops, L.

“…Objective: To date, only a small number of epidemiological studies on myelofibrosis have been performed. The current study aimed to characterize the…”
Get full text

Thrombotic Microangiopathy Following Intestinal Transplantation: A Single Center Experience by Dierickx, D, Monbaliu, D, De Rycke, A, Wisanto, E, Lerut, E, Devos, T, Meers, S, Darius, T, Ferdinande, P, Pirenne, J

“…Abstract Background Transplant-related thrombotic microangiopathy (TMA) is a well-recognized complication of all types of transplantations. Despite its known…”
Get full text